Insider · CIK 0001352620
Faheem Hasnain
Files at KURA (Kura Oncology, Inc.), GOSS (Gossamer Bio, Inc.). First filing Mar 24, 2025, latest Dec 10, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KURA: Kura Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 8Weak | Kura Oncology, Inc. | $110k 10,000 shares | -29% | +93% from low-12% from high | |
| 2Weak | Kura Oncology, Inc. | $181k 22,682 shares | -49% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | KURA Kura Oncology, Inc. | MOption exercise Common Stock10b5-1 | +10,000 | $3.12 | $31k | 33,983 | Dec 10, 2025 |
| Dec 9, 2025 | KURA Kura Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $10.98 | $110k | 23,983 | Dec 10, 2025 |
| Oct 1, 2025 | GOSS Gossamer Bio, Inc. | AGrant or award Common Stock | +437,500 | $0.00 | $0 | 557,793 | Oct 2, 2025 |
| Jun 5, 2025 | KURA Kura Oncology, Inc. | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Mar 21, 2025 | KURA Kura Oncology, Inc. | MOption exercise Common Stock10b5-1 | +22,682 | $6.32 | $143k | 46,665 | Mar 24, 2025 |
| Mar 21, 2025 | KURA Kura Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -22,682 | $8.00 | $181k | 23,983 | Mar 24, 2025 |
| Mar 4, 2025 | GOSS Gossamer Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,540,000 | $0.00 | $0 | 1,540,000 | Mar 6, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.